4 for referral for liver transplantation includes one of the following: Child-Pugh score of seven, model for end-stage liver disease (MELD) of 10, or any complication of portal hypertension. Overall, the results of liver transplantation are good with 70% in 10-year survival rates [21, 22]. The risk of developing colonic neoplasia in ulcerative colitis still persists after transplantation, and therefore annual colonoscopic surveillance is still warranted. In our patient, he has been regularly followed up with stable condition, and he is planned to have regular ultrasound imaging of hepatobiliary system and colonoscopic surveillance. References [1] R. Chapman, J. Fevery, A. Kalloo et al., “Diagnosis and management of primary sclerosing cholangitis,” Hepatology, vol. 51, no. 2, pp. 660–678, 2010. [2] K. Oberholzer, A. W. Lohse, P. Mildenberger et al., “Diagnosis of primary sclerosing cholangitis: prospective comparison of MR cholangiography with endoscopic retrograde cholangiog- raphy,” RoFo, vol. 169, no. 6, pp. 622–626, 1998. [3] B. Terjung, U. Spengler, T. Sauerbruch, and H. J. Worman, “’Atypical p-ANCA’ in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines,” Gastroenterology, vol. 119, no. 2, pp. 310–322, 2000. [4] S. Y. Bangarulingam, A. A. Gossard, B. T. Petersen, B. J. Ott, and K. D. Lindor, “Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis,” American Journal of Gastroenterology, vol. 104, no. 4, pp. 855– 860, 2009. [5] K. W. Burak, P. Angulo, and K. D. Lindor, “Is there a role for liver biopsy in primary sclerosing cholangitis?” American Journal of Gastroenterology, vol. 98, no. 5, pp. 1155–1158, 2003. [6] T. Kamisawa, N. Egawa, K. Tsuruta, A. Okamoto, and N. Funata, “Primary sclerosing cholangitis may be overestimated in Japan,” Journal of Gastroenterology, vol. 40, no. 3, pp. 318– 319, 2005. [7] T. J. Weism u¨ller, J. Wedemeyer, S. Kubicka, C. P. Strassburg, and M. P. Manns, “The challenges in primary sclerosing cholangitis—aetiopathogenesis, autoimmunity, management and malignancy,” Journal of Hepatology, vol. 48, no. 1, pp. S38– S57, 2008. [8] E. Schrupmf, K. Elgjo, O. Fausa, E. Gjone, F. Kolmannskog, and R. S. Sclerosing, “Sclerosing cholangitis in ulcerative colitis,” Scandinavian Journal of Gastroenterology, vol. 15, no. 6, pp. 689–697, 1980. [9] E. V. Loftus Jr., G. C. Harewood, C. G. Loftus et al., “PSC-IBD: a unique form of inﬂammatory bowel disease associated with primary sclerosing cholangitis,” Gut, vol. 54, no. 1, pp. 91–96, 2005. [10] K. Lundqvist and U. Broome´, “Diﬀerences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study,” Diseases of the Colon and Rectum, vol. 40, no. 4, pp. 451–456, 1997. [11] R. M. Soetikno, O. S. Lin, P. A. Heidenreich, H. S. Young, and M. O. Blackstone, “Increased risk of colorectal neoplasia in patiets with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis,” Gastrointestinal Endoscopy, vol. 56, no. 1, pp. 48–54, 2002. Case Reports in Medicine [12] K. D. Lindor, K. V. Kowdley, V. A. C. Luketic et al., “High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis,” Hepatology, vol. 50, no. 3, pp. 808–814, 2009. [13] G. Garcia-Tsao, A. J. Sanyal, N. D. Grace et al., “Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis,” Hepatology, vol. 46, no. 3, pp. 922– 938, 2007. [14] A. Stiehl, G. Rudolph, P. Klo¨ters-Plachky, P. Sauer, and S. Walker, “Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment,” Journal of Hepatology, vol. 36, no. 2, pp. 151–156, 2002. [15] G. R. May, C. E. Bender, N. F. LaRusso, and R. H. Wiesner, “Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis,” American Journal of Roentgenology, vol. 145, no. 5, pp. 1061–1064, 1985. [16] D. J. Brandt, R. L. MacCarty, J. W. Charboneau, N. F. LaRusso, R. H. Wiesner, and J. Ludwig, “Gallbladder disease in patients with primary sclerosing cholangitis,” American Journal of Roentgenology, vol. 150, no. 3, pp. 571–574, 1988. [17] K. Burak, P. Angulo, T. M. Pasha, K. Egan, J. Petz, and K. D. Lindor, “Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis,” American Journal of Gastroen- terology, vol. 99, no. 3, pp. 523–526, 2004. [18] D. J. Rea, J. K. Heimbach, C. B. Rosen et al., “Liver transplantation with neoadjuvant chemoradiation is more eﬀective than resection for hilar cholangiocarcinoma,” Annals of Surgery, vol. 242, no. 3, pp. 451–461, 2005. [19] K. M. Boberg, A. Bergquist, S. Mitchell et al., “Cholangio- carcinoma in primary sclerosing cholangitis: risk factors and clinical presentation,” Scandinavian Journal of Gastroenterol- ogy, vol. 37, no. 10, pp. 1205–1211, 2002. [20] G. Rudolph, D. Gotthardt, P. Klo¨ters-Plachky, H. Kulaksiz, D. Rost, and A. Stiehl, “Inﬂuence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis,” Journal of Hepatology, vol. 51, no. 1, pp. 149–155, 2009. [21] P. J. Gow, “Liver transplantation for primary sclerosing cholangitis,” Liver, vol. 20, pp. 97–103, 2000. [22] I. W. Graziadei, “Recurrence of primary sclerosing cholangitis after liver transplantation,” Liver Transplantation, vol. 8, no. 7, pp. 575–581, 2002.